5th Floor, Brigade Towers,
Financial District, Gachibowli,
Hyderabad - 500032,
The market is segmented by Test Type, Product, Usability (Disposable, Reusable), Application, and End User.
Brazil is a country with a growing middle class, stabilizing economy, increasing urban population, and a supportive government. The country is showing a major shift in the private health sector, which is a supporting factor for the IVD market. The Brazilian healthcare funding is supported by the Ministry of Health, which runs the government hospitals in the country. The rising interest of the Brazilian researchers in molecular testing technologies, prenatal screening, and point of care (POC) glucose testing are the primary factors augmenting the growth of the IVD market in Brazil. According to the National Institute of Health, the prevalence of diabetes in Brazil was around 6.3% to 13.5% in 2016. This rising prevalence of diabetes in the country is propelling the growth of the in vitro diagnostics in Brazil. Therefore, factors, such as the rising interest of the Brazilian researchers in advanced diagnostics and high prevalence of chronic diseases are contributing to the growth of the IVD market in the country.
As per the scope of this report, in vitro diagnostics involves medical devices and consumables that are utilized to perform in vitro tests on various biological samples. They are used for the diagnosis of various medical conditions, such as chronic diseases. In this report, a detailed analysis of the in vitro diagnostics market is presented, with specific attention toward diabetes and thalassemia.
|Disposable IVD Devices|
|Reusable IVD Devices|
|Hospitals & Clinics|
|Other End Users|
Report scope can be customized per your requirements. Click here.
Molecular diagnostic devices are used to analyze biological markers in the genome and proteome to detect pathogens or mutations. On the basis of technology used, molecular diagnostic devices can be segmented into chips and microarrays, mass spectroscopy, next-generation sequencing (NGS), polymerase chain reaction (PCR)-based methods, cytogenetic, and molecular imaging. Factors, such as large outbreaks of bacterial and viral epidemics in the world, increasing demand for point-of-care diagnostics, and rapidly evolving technology, are driving the growth of the molecular diagnostics segment. Molecular diagnostics and pharmacogenomics can be used to reduce the adverse effects and toxicity of pharmaceutical interventions, and facilitate cost-effective therapy by avoiding unnecessary expensive drugs, optimizing doses and timing, and eliminating ineffective drugs. The field is rapidly evolving and remains attractive to academia and the industry. The use of molecular diagnostic techniques in the development and subsequent administration of personalized medicine is likely to boost the market growth.
To understand key trends, Download Sample Report
BioMérieux, Danaher Corporation, Roche Diagnostics, Becton, Dickinson and Company, and Bio-Rad Laboratories Inc., are some of the major players in the market. The major companies are focusing on increasing technological advancements, in order to address customer needs, like fully automated systems, which reduces manual processes and consumables and also provides fast and accurate results.
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 High Prevalence of Chronic Diseases
4.2.2 Increasing Use of Point-of-care (POC) Diagnostics
4.2.3 Advanced Technologies
4.2.4 Increasing Awareness and Acceptance of Personalized Medicine and Companion Diagnostics
4.3 Market Restraints
4.3.1 Stringent Regulations
4.3.2 Cumbersome Reimbursement Procedures
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION
5.1 By Technique
5.1.1 Clinical Chemistry
5.1.2 Molecular Diagnostics
5.1.3 Immuno Diagnostics
5.1.5 Other Types
5.2 By Product
5.2.3 Other Products
5.3 By Usability
5.3.1 Disposable IVD Devices
5.3.2 Reusable IVD Devices
5.4 By Application
5.4.1 Infectious Disease
5.4.5 Autoimmune Disease
5.4.7 Other Applications
5.5 End Users
5.5.1 Diagnostic Laboratories
5.5.2 Hospitals & Clinics
5.5.3 Other End Users
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Abbott Laboratories
6.1.2 Arkray Inc.
6.1.3 Becton, Dickinson and Company
6.1.5 Bio-Rad Laboratories Inc.
6.1.6 Danaher Corporation
6.1.8 Roche Diagnostics
6.1.9 Siemens AG
6.1.10 Thermo Fisher Scientific
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments